Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke Patients
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 56
- Registration Number
- NCT04652128
- Locations
- 🇰🇷
Yonsei Severance Hospital, Seoul, Korea, Republic of
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04597931
Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Lithuanian University of Health Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT04498715
- Locations
- 🇱🇹
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania
The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Martina Hansen's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04303026
- Locations
- 🇳🇴
Martina Hansens Hospital, Sandvika, Norway
Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 80
- Registration Number
- NCT04115397
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT04087096
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Osteoporosis in Primary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 40
- Registration Number
- NCT04085419
- Locations
- 🇸🇮
Endocrinology Department, Ljubljana, Slovenia
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
- Conditions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04045522
- Locations
- 🇨🇳
People's Hospital of Liaoning Province, Shenyang, Liaoning, China
🇨🇳Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Kwong Wah Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04034199
- Locations
- 🇭🇰
Kwong Wah Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.